Editorial

Personalized Treatment of Vulvar Cancer

Ottavia D’Oria1, Giacono Corrado2, Enrico Vizza3, Vito Chiantera4, Antonio Simone Laganà1,*

1Department of Medical and Surgical Sciences and Translational Medicine, PhD Course in “Translational Medicine and Oncology”, Sapienza University, 00185 Rome, Italy
2Gynecologic Oncology Unit, Women Wealth Area, Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, 00168 Rome, Italy
3Gynecologic Oncology Unit, Department of Experimental Clinical Oncology, IRCCS-Regina Elena National Cancer Unit Institute, 00144 Rome, Italy
4Unit of Gynecologic Oncology, ARNAS “Civico – Di Cristina – Benfratelli”, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, 90133 Palermo, Italy

*Correspondence: andrea.giannini@uniroma1.it (Andrea Giannini)

Submitted: 10 August 2022 Revised: 14 August 2022 Accepted: 23 August 2022 Published: 28 October 2022

Vulvar cancer (VC) accounts for 5% of all gynecologic cancer and the most common histological type is squamous cell carcinoma (up to 90%) [1].

The median age of VC is over 65 years, but in the past decades the incidence of VC in young women is rising, related to Human Papilloma Virus Infection (HPV) [2]. The staging of vulvar cancer is surgical, based on the 2009 Federation International de Gynecologie et Obstetrique (FIGO) and American Joint Committee on Cancer (AJCC) Seventh Staging Edition TNM (Tumor, Node, Metastasis) staging [3].

Over the last years, the surgical treatment of VC tumor is changed, from invasive technique to more conservative approach, and becoming as personalized as possible. The original radical vulvectomy approach with en bloc bilateral inguinal-femoral lymphadenectomy was burdened with a high complication rate: infection, necrosis of tissues, pain, functional and body image distortion, deterioration of sexual life and psychological health, making the postoperative management of this tumor very difficult [4]. The modified radical vulvectomy includes superficial and deep fascia lata, with separate incisions for tumor and groin node dissection, sparing several complications [5]. Minimal resection margins were introduced, limited to the tumor (from 1 to 2 cm according to Heaps’ study) [6]. Di Saia et al. [7] have shown that an alternative approach for early VC is possible, including 20 patients affected by non-invasive VC and comparing wide local excision with radical vulvectomy: the 18 patients who underwent wide local excision have preserved sexual function, assessing prgasm and dyspareunia. The National Comprehensive Cancer Network (NCCN) Guidelines recommend re-excision of positive margins or those classified as close (<8 mm); different studies focused on the safety of smaller margins [8].

A big step in the personalized approach to vulvar cancer was represented by postoperative reconstruction [9,10], based on patients’ characteristics and anatomy, with a big improvement of aesthetic results in these patients. The postoperative reconstruction includes two types of Flaps: Advancement Flap (V-Y Gluteal Fold Flap; Medial Thigh Flap) and Transpositional Flap (Lotus Petal Flap; Gluteal Thigh Flap; Gluteal Fold Flap and Anterolateral Thigh Flap [11,12].

Despite different studies demonstrating feasibility of sentinel node (SLN) biopsy in VC early stages, in more than 50% of the cases inguinoferomal lymphadenectomy is still performed, with high-risk of complications (infection, lymphedema and erysipelas/lymphangitis). Different studies tried to reduce complications of deep lymphadenectomy [13], proposing preservation of the deep fascia, video-endoscopic minimally invasive inguinal lymphadenectomy (VEIL) or sartorius muscle transposition, without significative results. A recent study tried to assess the feasibility and safety of a retrograde extraverteral translinguinal novel approach to pelvic lymphadenectomy (TRIPLE) in vulvar cancer patients [14]. Moreover, some specific anatomical sites, such as genital lymphedema, are extremely intrusive in private life, creating discomfort and psychological and there is no consensus about the kind and timing of treatment. Currently SLN biopsy is the gold standard for surgical treatment of VC with size ≤4 cm and clinically and/or radiological negative inguinoferomal lymph node [2]. If SLN is positive, the management is debated (lymphadenectomy vs external beam radiation therapy (EBRT)). Different studies tried to confirm the safety and feasibility of SLN, sparing patients the complications of lymphadenectomy: GROINSS-V data showed that in patients with negative biopsy, groin recurrence rate was only 2% after almost 3 years and no significative differences with patients with early-stage vulvar cancer treated with groin lymphadenectomy were registered [15]. For patients with stage IIIB, IIIC, and IVA, the gold standard is chemoradiation to the vulvar tumor, groin, and pelvis [1]. Surgical approach after chemoradiation it is considered on a case-by-case basis.

Recurrence rate in VC is 15%–35% and surgery is the most adequate treatment of local recurrence, basing the type
of surgery no only on the dimension of vulvar recurrence but on performance status of patients and previous treatment.

Surgical treatment of VC has evolved in the last years, trying to reduce mutilating results and promoting a personalized approach, considering sexual life and psychological compromission of these patients too.

**Author Contributions**

AG—conceptualization; ASL and OD—writing original draft preparation; GC and VC—writing review and editing; EV—visualization; AG—supervision. All authors have read and agreed to the published version of the manuscript.

**Ethics Approval and Consent to Participate**

Not applicable.

**Acknowledgment**

Not applicable.

**Funding**

This research received no external funding.

**Conflict of Interest**

The authors declare no conflict of interest. ASL is serving as the Editorial Board members and Guest editors of this journal. OD and AG are serving as the Guest editors of this journal. We declare that OD, ASL and AG had no involvement in the peer review of this article and has no access to information regarding its peer review. Full responsibility for the editorial process for this article was delegated to MHD.

**References**

[1] Greer BE, Koh W. New NCCN Guidelines for Vulvar Cancer. Journal of the National Comprehensive Cancer Network. 2016; 14: 656–658.

[2] Giannini A, D’Oria O, Chiofalo B, Bruno V, Baiocco E, Mancini E, et al. The giant steps in surgical downsizing toward a personalized treatment of vulvar cancer. Journal of Obstetrics and Gynaecology Research. 2022; 48: 533–540.

[3] FIGO Committee on Gynecologic Oncology. FIGO staging for carcinoma of the vulva, cervix, and corpus uteri. International Journal of Gynecology & Obstetrics. 2014; 125: 97–98.

[4] Hacker NF, Leuchter RS, Berek JS, Castaldo TW, Lagasse LD. Radical vulvectomy and bilateral inguinal lymphadenectomy through separate groin incisions. Obstetrics and Gynecology. 1981; 58: 574–579.

[5] Gitas G, Propp E, Baum S, Krugel M, Rody A, Tsolakidis D, et al. A risk factor analysis of complications after surgery for vulvar cancer. Archives of Gynecology and Obstetrics. 2021; 304: 511–519.

[6] Heaps JM, Fu YS, Montez FJ, Hacker NF, Berek JS. Surgical-pathologic variables predictive of local recurrence in squamous cell carcinoma of the vulva. Gynecologic Oncology. 1990; 38: 309–314.

[7] DiSaia PJ, Creasman WT, Rich WM. An alternate approach to early cancer of the vulva. American Journal of Obstetrics and Gynecology. 1979; 133: 825–832.

[8] Schults CD, Blitzblau R, Aasi SZ, Alam M, Andersen JS, Baumann BC, et al. NCCN Guidelines®Insights: Squamous Cell Skin Cancer, Version 1.2022. Journal of the National Comprehensive Cancer Network. 2021; 19: 1382–1394.

[9] Franchi M, Ucella S, Zorzato PC, Dalle Carbonare A, Garzon S, Lagana AS, et al. Vaginal flap for urethral neomateus reconstruction after radical surgery for vulvar cancer: a retrospective cohort analysis. International Journal of Gynecologic Cancer. 2019; 29: 1098–1104.

[10] Milliken S, May J, Sanderson PA, Congiu MA, D’Oria O, Golia D’Augé T, et al. Reducing the radicality of surgery for vulvar cancer: are smaller margins safer? Minerva Obstetrics and Gynecology. 2021; 73: 160–165.

[11] Giannini A, Di Donato V, D’Oria O, Schiavi MC, May J, Benedetti Panici P, et al. The V-V gluteraldehyde advancement flap: Outcomes following radical surgery for vulvar malignancies. International Journal of Gynecology Obstetrics. 2021; 152: 421–424.

[12] Giannini A, D’Oria O, Santangelo G, Allegrini CM, Caruso G, Di Pinto A, et al. The role of the sentinel lymph node in vulvar cancer. Minerva Ginecologica. 2020; 72: 361–366.

[13] Baggio S, Lagana AS, Garzon S, Scollo M, Raffaelli R, Tateo S, et al. Efficacy of a collagen-fibrin sealant patch (TachoSil®) as adjuvant treatment in the inguinofemoral lymphadenectomy for vulvar cancer: a double-blind randomized-controlled trial. Archives of Gynecology and Obstetrics. 2019; 299: 1467–1474.

[14] Garganese G, Fragomeni SM, Della Corte L, Conte C, Marinucci B, Tagliaferri L, et al. Trans-inguinal pelvic lymphadenectomy in vulvar cancer patients: TRIPLE pilot study. International Journal of Gynecologic Cancer. 2022; 32: 846–852.

[15] Van der Zee AGJ, Oonk MH, De Hulst JA,Ansink AC, Vergote I, Verheijen RH, et al. Sentinel Node Dissection is Safe in the Treatment of Early-Stage Vulvar Cancer. Journal of Clinical Oncology. 2008; 26: 884–889.